Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?
- PMID: 22343812
- DOI: 10.1038/clpt.2011.337
Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?
Abstract
As the pharmaceutical industry productivity crisis worsens, there are calls for regulatory changes to support innovation. At the same time, prescribers and payers desire more information about drugs at the time they are released to the market. Will new regulatory schemes be able to accommodate these disparate needs?
Comment on
-
Adaptive licensing: taking the next step in the evolution of drug approval.Clin Pharmacol Ther. 2012 Mar;91(3):426-37. doi: 10.1038/clpt.2011.345. Epub 2012 Feb 15. Clin Pharmacol Ther. 2012. PMID: 22336591 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
